7
Nov
2019

Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Lilly’s Half-Measure on Insulin, Illumina’s Up-Market Play, & the Little Deals from SF
MRNA Vaccines Impress, Blueprint Wins First FDA OK, & Calif. Gov. Stares Down Biotech on the Eve of #JPM20
Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump